SCHEMBL19902708

SCHEMBL19902708

Cn1cnc2cc(C(=O)N[C@H]3CC[C@H](c4n[nH]c(=O)c5ccccc54)CC3)ccc21

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.48
ALDH1A1 P00352 4/20 0.48
NPC1 O15118 2/20 0.48
TP53 P04637 7/20 0.46
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MAPT P10636 4/20 0.44
SMYD3 Q9H7B4 1/20 0.44
ROCK2 O75116 1/20 0.43
NAMPT P43490 1/20 0.42
POLB P06746 1/20 0.41
CHRNA7 P36544 1/20 0.41
LMNA P02545 1/20 0.40
THRB P10828 1/20 0.40
USP2 O75604 1/20 0.40
RAB9A P51151 1/20 0.40
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17452847 0.90 ROCK2 (0.55) HPGDALDH1A1NPC1TP53HTT
SCHEMBL19902469 0.89 HCAR3 (0.47) HPGDALDH1A1NPC1TP53HTT
SCHEMBL19902707 0.85 KDM5A (0.49) HPGDALDH1A1ROCK2CHRNA7KDM4E
SCHEMBL19902622 0.83 MAPK14 (0.54) HPGDALDH1A1ROCK2CHRNA7KDM4E
SCHEMBL19902501 0.82 PTGER3 (0.47) HPGDALDH1A1ROCK2KDM4E
SCHEMBL19902696 0.81 NPC1 (0.50) HPGDALDH1A1NPC1SMYD3ROCK2
SCHEMBL19902479 0.80 KHK (0.48) HPGDALDH1A1ROCK2KDM4E
SCHEMBL17452834 0.80 ROCK2 (0.53) HPGDALDH1A1NPC1TP53HTT
SCHEMBL19902585 0.79 CHEK1 (0.47) HPGDALDH1A1NPC1SMYD3ROCK2
SCHEMBL19902713 0.78 TNKS (0.50) ALDH1A1NPSR1MAPTROCK2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 HPGD 749/4885ALDH1A1 1252/4885NPC1 2709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.